On this episode of Biotalk, Locust Walk‘s Andy Meyerson welcomes Helen Ho, Chief Business Officer of Blueprint Medicines, to the podcast. Blueprint Medicines is a pioneering global precision therapy company committed to crafting life-altering medications for individuals with cancer and blood disorders. During the conversation, Helen shares her journey into biotech realm, and ultimately, Blueprint. She delves into the unique experience of stepping into the role of CBO, a position previously held by the CEO, and the intriguing dynamics that come with such a transition. Helen provides insights into how Blueprint strategically navigated the turbulent waters of the ever-evolving biotech landscape. She discusses the pivotal role that the shift towards commercialization played in helping the company adapt to the current disruptions and challenges in the biotech industry. We invite you to tune in to this engaging podcast episode. Subscribe or follow Biotalk on Apple Podcasts | Spotify.   Timestamps: 2:00: What attracted you to biology and to industry, particularly biotech? 6:55: What is the biggest thing that you’ve learned from each of your prior roles that enables you to be successful in your current position at one of the faster growing biotechs? 8:58: What dr

0 Comments Sort By